ASX:IIQ INOVIQ (IIQ) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free IIQ Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield15.56%Price TargetN/A Stock AnalysisStock Analysis Get INOVIQ alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now. About INOVIQINOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.Read More Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now. IIQ Stock News HeadlinesAugust 31, 2023 | finance.yahoo.comINOVIQ Full Year 2023 Earnings: AU$0.097 loss per share (vs AU$0.20 loss in FY 2022)August 16, 2023 | finance.yahoo.comIIQ.AX - INOVIQ LtdApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.August 14, 2023 | finance.yahoo.comEXCELLENT CLINICAL DATA FOR SUBB2M/CA15-3 BREAST CANCER TESTAugust 14, 2023 | finance.yahoo.comINOVIQ (ASX:IIQ) shareholders have earned a 17% CAGR over the last five yearsOctober 28, 2022 | finance.yahoo.comWe're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash WiselySee More Headlines Receive IIQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INOVIQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:IIQ CUSIPN/A CIKN/A Webwww.inoviq.com Phone61 3 9548 7586FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.85% Return on Assets-19.14% Debt Debt-to-Equity Ratio3.41 Current Ratio4.94 Quick Ratio9.52 Sales & Book Value Annual Sales$1.58 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.18 per share Price / BookN/AMiscellaneous Outstanding Shares92,020,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.20 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Leearne Maree Hinch B.Sc.B.V.M.S., BSc., M.B.A., M.R.C.V.S., Chief Executive OfficerMr. Mark Edwards BAccC.A., CA, CFO & Company SecretaryProf. Gregory Edward Rice BSc (Hons)GradDipMgt, MHA, Ph.D., Chief Scientific OfficerKey CompetitorsANGLEOTCMKTS:ANPCYAustralian Clinical LabsASX:ACLBARD1 Life SciencesASX:BD1BCAL DiagnosticsASX:BDXbioAffinity TechnologiesNASDAQ:BIAFWView All Competitors This page (ASX:IIQ) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmith“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INOVIQ Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
